AIRLINK 62.20 Decreased By ▼ -0.28 (-0.45%)
BOP 5.34 Decreased By ▼ -0.02 (-0.37%)
CNERGY 4.48 Decreased By ▼ -0.10 (-2.18%)
DFML 15.40 Decreased By ▼ -0.10 (-0.65%)
DGKC 66.29 Decreased By ▼ -0.11 (-0.17%)
FCCL 17.35 Decreased By ▼ -0.24 (-1.36%)
FFBL 27.65 Decreased By ▼ -0.05 (-0.18%)
FFL 9.27 No Change ▼ 0.00 (0%)
GGL 10.08 Increased By ▲ 0.02 (0.2%)
HBL 106.00 Increased By ▲ 0.30 (0.28%)
HUBC 122.04 Decreased By ▼ -0.26 (-0.21%)
HUMNL 6.55 Decreased By ▼ -0.05 (-0.76%)
KEL 4.52 Increased By ▲ 0.02 (0.44%)
KOSM 4.40 Decreased By ▼ -0.08 (-1.79%)
MLCF 35.90 Decreased By ▼ -0.30 (-0.83%)
OGDC 123.05 Increased By ▲ 0.13 (0.11%)
PAEL 22.90 Decreased By ▼ -0.10 (-0.43%)
PIAA 30.73 Increased By ▲ 1.39 (4.74%)
PIBTL 5.85 Increased By ▲ 0.05 (0.86%)
PPL 107.73 Increased By ▲ 0.23 (0.21%)
PRL 27.21 Decreased By ▼ -0.04 (-0.15%)
PTC 17.56 Decreased By ▼ -0.51 (-2.82%)
SEARL 53.19 Increased By ▲ 0.19 (0.36%)
SNGP 62.85 Decreased By ▼ -0.36 (-0.57%)
SSGC 10.74 Decreased By ▼ -0.06 (-0.56%)
TELE 9.10 Decreased By ▼ -0.10 (-1.09%)
TPLP 11.55 Increased By ▲ 0.11 (0.96%)
TRG 70.75 Decreased By ▼ -0.11 (-0.16%)
UNITY 23.80 Increased By ▲ 0.18 (0.76%)
WTL 1.28 No Change ▼ 0.00 (0%)
BR100 6,947 Increased By 3.6 (0.05%)
BR30 22,802 Decreased By -24.8 (-0.11%)
KSE100 67,149 Increased By 6.5 (0.01%)
KSE30 22,091 Increased By 1.3 (0.01%)
World

Singapore approves anti-viral drug for COVID-19 patients

  • The US authorised the emergency use of remdesivir in hospitals at the start of May, followed by Japan and South Korea, while Europe has been considering following suit.
Published June 10, 2020

SINGAPORE: Singapore has approved the use of the anti-viral drug remdesivir to treat seriously ill coronavirus patients, authorities said Wednesday, becoming the latest country to do so.

The US authorised the emergency use of remdesivir in hospitals at the start of May, followed by Japan and South Korea, while Europe has been considering following suit.

It has been granted conditional approval in Singapore for treatment of some adult virus patients, such as those who require intensive breathing support, the country's health products regulator said.

The regulator, the Health Sciences Authority, said it had "expedited the review of remdesivir given the urgent public health need during the COVID-19 pandemic".

As a condition for the approval, the authority requires US-based Gilead Sciences, which developed the drug, to collect safety data and monitor its use.

Singapore initially kept the virus in check with a strict regime of testing and contact tracing, only for serious outbreaks to emerge later in dormitories housing low-paid foreign workers.

The city-state now has the highest recorded number of infections in Southeast Asia with nearly 39,000 cases, mostly among foreign workers. The death toll stands at 25.

Comments

Comments are closed.